News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
72,378 Results
Type
Article (1985)
Company Profile (2)
Press Release (70391)
Multimedia
Podcasts (1)
Webinars (1)
Section
Business (21608)
Career Advice (10)
Deals (4567)
Drug Development (8222)
FDA (1812)
Job Trends (817)
News (37223)
Policy (3568)
Tag
Academia (96)
Accelerated approval (2)
Adcomms (1)
Allergies (16)
Alliances (8182)
ALS (12)
Alzheimer's disease (157)
Antibody-drug conjugate (ADC) (63)
Approvals (1921)
Artificial intelligence (26)
Autoimmune disease (12)
Automation (1)
Bankruptcy (8)
Best Places to Work (592)
Biosimilars (63)
Biotechnology (5)
Bladder cancer (26)
Brain cancer (5)
Breast cancer (52)
Cancer (499)
Cardiovascular disease (18)
Career advice (10)
CAR-T (13)
Cell therapy (68)
Cervical cancer (3)
Clinical research (7469)
Collaboration (247)
Compensation (17)
Complete response letters (5)
COVID-19 (198)
C-suite (65)
Cystic fibrosis (6)
Data (580)
Depression (11)
Diabetes (30)
Diagnostics (621)
Digital health (4)
Drug discovery (33)
Drug pricing (1)
Duchenne muscular dystrophy (30)
Earnings (7975)
Events (7383)
Executive appointments (62)
FDA (2198)
Fibrodysplasia Ossificans Progressiva (1)
Funding (121)
Gene editing (7)
Generative AI (1)
Gene therapy (32)
GLP-1 (67)
Government (236)
Grass and pollen (1)
Guidances (38)
Healthcare (1088)
HIV (1)
Huntington's disease (2)
IgA nephropathy (18)
Immunology and inflammation (6)
Immuno-oncology (5)
Indications (12)
Infectious disease (212)
Inflammatory bowel disease (23)
Inflation Reduction Act (1)
Influenza (11)
Intellectual property (32)
IPO (1652)
Job creations (247)
Job search strategy (10)
JPM (3)
Labor market (1)
Layoffs (13)
Legal (954)
Liver cancer (20)
Lung cancer (91)
Lymphoma (38)
Manufacturing (86)
MASH (12)
Medical device (1156)
Medtech (1163)
Mergers & acquisitions (3075)
Metabolic disorders (73)
Multiple sclerosis (16)
NASH (1)
Neurodegenerative disease (25)
Neuropsychiatric disorders (5)
Neuroscience (268)
NextGen: Class of 2026 (225)
Non-profit (65)
Obesity (26)
Opinion (1)
Ovarian cancer (21)
Pain (11)
Pancreatic cancer (15)
Parkinson's disease (32)
Partnered (3)
Patents (50)
Patient recruitment (47)
Peanut (1)
People (5166)
Pharmaceutical (2)
Pharmacy benefit managers (4)
Phase 1 (2042)
Phase 2 (3144)
Phase 3 (2823)
Pipeline (571)
Policy (1)
Postmarket research (242)
Preclinical (695)
Press Release (2)
Prostate cancer (20)
Psychedelics (3)
Radiopharmaceuticals (22)
Rare diseases (62)
Real estate (608)
Regulatory (2880)
Reports (9)
Research institute (97)
RNA editing (2)
RSV (2)
Schizophrenia (18)
Series A (23)
Series B (21)
Service/supplier (1)
Sickle cell disease (6)
Spinal muscular atrophy (5)
Sponsored (1)
Startups (429)
Stomach cancer (1)
Supply chain (12)
The Weekly (1)
Vaccines (40)
Venture capital (5)
Weight loss (5)
Women's health (4)
Date
Today (1)
Last 7 days (50)
Last 30 days (221)
Last 365 days (2755)
2026 (289)
2025 (2710)
2024 (3302)
2023 (3846)
2022 (7047)
2021 (6403)
2020 (5916)
2019 (3883)
2018 (3019)
2017 (3589)
2016 (3190)
2015 (4056)
2014 (3022)
2013 (2600)
2012 (2775)
2011 (2902)
2010 (2663)
Location
Africa (88)
Alabama (3)
Arizona (11)
Asia (21985)
Australia (2461)
California (642)
Canada (373)
China (367)
Colorado (5)
Connecticut (21)
Delaware (7)
Europe (13183)
Florida (61)
Georgia (13)
Illinois (31)
India (34)
Indiana (13)
Japan (240)
Kansas (5)
Louisiana (1)
Maine (4)
Maryland (104)
Massachusetts (486)
Michigan (7)
Minnesota (34)
Missouri (3)
Nebraska (2)
Nevada (9)
New Hampshire (1)
New Jersey (378)
New York (226)
North Carolina (90)
Northern California (272)
Ohio (3)
Oregon (1)
Pennsylvania (120)
Rhode Island (1)
South America (108)
Southern California (299)
Tennessee (1)
Texas (52)
United States (2406)
Utah (24)
Virginia (44)
Washington D.C. (3)
Washington State (47)
Wisconsin (7)
72,378 Results for "adaptimmune ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Adaptimmune Announces Changes to Board and Executive Leadership Team
November 17, 2025
·
7 min read
Press Releases
Adaptimmune Announces Delisting from Nasdaq
October 20, 2025
·
6 min read
Press Releases
Adaptimmune Reports Q2 Financial Results and Provides Business Update
August 13, 2025
·
1 min read
Business
Adaptimmune Raises ‘Substantial Doubt’ About Business Despite First-in-Class T Cell Therapy
Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its approval in August 2024. Nevertheless, it is pausing development of two oncology assets to save money.
March 21, 2025
·
2 min read
·
Tristan Manalac
Cancer
Adaptimmune Plots Path to FDA as Sarcoma Cell Therapy Aces Pivotal Trial
Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA submission to the FDA, set to start by the end of 2025.
November 14, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Adaptimmune Provides Q4 and Full Year 2024 Business Update
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026 Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programs At the end of 2024, Adaptimmune had Total Liquidity1 of $152 million Evaluating all strategic options to maximize shareholder value
March 20, 2025
·
7 min read
Press Releases
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
January 19, 2026
·
4 min read
Press Releases
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
January 29, 2026
·
3 min read
Press Releases
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025
December 19, 2024
·
4 min read
Press Releases
Faron Pharmaceuticals Ltd: Appointment of CFO
December 1, 2025
·
3 min read
1 of 7,238
Next
